Article Text

Download PDFPDF
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix
  1. Kosei Hasegawa, MD, PhD*,
  2. Shoji Nagao, MD, PhD,
  3. Masanori Yasuda, MD, PhD*,
  4. David Millan, MD§,
  5. Akila N. Viswanathan, MD,
  6. Rosalind M. Glasspool, MBBS, PhD, FRCP,
  7. Mojgan Devouassoux-Shisheboran, MD,
  8. Alan Covens, MD#,
  9. Domenica Lorusso, MD**,
  10. Christian Kurzeder, MD,,
  11. Jae-Weon Kim, MD,,
  12. Laurence Gladieff, MD§§,
  13. Jane Bryce, MSN¶¶,
  14. Michael Friedlander, MBChB, FRACP, PhD∥∥ and
  15. Keiichi Fujiwara, MD, PhD*
  1. *Saitama Medical University International Medical Center, Saitama, Japan (GOTIC);
  2. Hyogo Cancer Center, Akashi, Japan (GOTIC);
  3. Harvard Medical School, Boston, MA (RTOG);
  4. §Southern General Hospital, Glasgow, Lanarkshire, UK;
  5. Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK (SGCTG);
  6. Hospices Civils de Lyon, Lyon, France (GINECO);
  7. #Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada (GOG);
  8. **Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy (MITO);
  9. ††Kliniken Essen Mitte, Essen, Germany (AGO);
  10. ‡‡Seoul National University College of Medicine, Seoul, Korea (KGOG);
  11. §§Institut Claudius Regaud, Toulouse, France (GINECO);
  12. ¶¶Instituto Nazionale Tumori, Napoli, Italy (MITO); and
  13. ∥∥Prince of Wales Hospital, Sydney, Australia (ANZGOG).
  1. Address correspondence and reprint requests to Keiichi Fujiwara, MD, PhD, Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1, Yamane, Hidaka City, Saitama, Japan. E-mail: fujiwara{at}


Abstract Clear cell carcinomas of the uterine corpus and cervix are rare gynecological cancers with limited information regarding the pathogenesis and biology. At present, the approach to management is the same as for patients with the more common histological subtypes of endometrioid endometrial cancer and adenocarcinoma of the cervix. Surgical resection is the standard treatment for patients with early-stage disease, but there is no evidence-based approach to direct the management of patients with more advanced-stage disease at presentation or with recurrent disease. We review the epidemiology, pathology, and what is known about both uterine corpus and cervical clear cell cancers and make management recommendations.

  • Clear cell carcinoma
  • Uterine corpus
  • Uterine cervix
  • Histological feature
  • Immunohistochemical
  • Treatment

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • The authors declare no conflicts of interest.